A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

NCT02960906 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Metastatic Renal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Pazopanib
DRUG: Sunitinib

Sponsor

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie